Literature DB >> 29019062

Adding metyrapone to chemotherapy plus mitotane for Cushing's syndrome due to advanced adrenocortical carcinoma.

Mélanie Claps1, Sara Cerri1, Salvatore Grisanti1, Barbara Lazzari1, Vittorio Ferrari1, Elisa Roca1, Paola Perotti2, Massimo Terzolo2, Sandra Sigala3, Alfredo Berruti4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29019062     DOI： 10.1007/s12020-017-1428-9

Source DB:  PubMed          Journal:  Endocrine        ISSN： 1355-008X            Impact factor:   3.633


× No keyword cloud information.
  16 in total

1.  Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma.

Authors:  Pasqualino Malandrino; Abir Al Ghuzlan; Marine Castaing; Jacques Young; Bernard Caillou; Jean-Paul Travagli; Dominique Elias; Thierry de Baere; Clarisse Dromain; Angelo Paci; Philippe Chanson; Martin Schlumberger; Sophie Leboulleux; Eric Baudin
Journal:  Endocr Relat Cancer       Date:  2010-08-16       Impact factor: 5.678

2.  Effectiveness of Metyrapone in Treating Cushing's Syndrome: A Retrospective Multicenter Study in 195 Patients.

Authors:  Eleni Daniel; Simon Aylwin; Omar Mustafa; Steve Ball; Atif Munir; Kristien Boelaert; Vasileios Chortis; Daniel J Cuthbertson; Christina Daousi; Surya P Rajeev; Julian Davis; Kelly Cheer; William Drake; Kirun Gunganah; Ashley Grossman; Mark Gurnell; Andrew S Powlson; Niki Karavitaki; Isabel Huguet; Tara Kearney; Kumar Mohit; Karim Meeran; Neil Hill; Aled Rees; Andrew J Lansdown; Peter J Trainer; Anna-Elisabeth H Minder; John Newell-Price
Journal:  J Clin Endocrinol Metab       Date:  2015-09-09       Impact factor: 5.958

Review 3.  Management of adrenal cancer: a 2013 update.

Authors:  M Terzolo; F Daffara; A Ardito; B Zaggia; V Basile; L Ferrari; A Berruti
Journal:  J Endocrinol Invest       Date:  2014-03       Impact factor: 4.256

4.  Plasma concentrations of o,p'DDD, o,p'DDA, and o,p'DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study.

Authors:  Ilse G Hermsen; Martin Fassnacht; Massimo Terzolo; Saskia Houterman; Jan den Hartigh; Sophie Leboulleux; Fulvia Daffara; Alfredo Berruti; Rita Chadarevian; Martin Schlumberger; Bruno Allolio; Harm R Haak; Eric Baudin
Journal:  J Clin Endocrinol Metab       Date:  2011-04-06       Impact factor: 5.958

5.  Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  A Berruti; E Baudin; H Gelderblom; H R Haak; F Porpiglia; M Fassnacht; G Pentheroudakis
Journal:  Ann Oncol       Date:  2012-10       Impact factor: 32.976

6.  Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial.

Authors:  Alfredo Berruti; Massimo Terzolo; Paola Sperone; Anna Pia; Silvia Della Casa; David J Gross; Carlo Carnaghi; Paolo Casali; Francesco Porpiglia; Franco Mantero; Giuseppe Reimondo; Alberto Angeli; Luigi Dogliotti
Journal:  Endocr Relat Cancer       Date:  2005-09       Impact factor: 5.678

7.  Combination chemotherapy in advanced adrenocortical carcinoma.

Authors:  Martin Fassnacht; Massimo Terzolo; Bruno Allolio; Eric Baudin; Harm Haak; Alfredo Berruti; Staffan Welin; Carmen Schade-Brittinger; André Lacroix; Barbara Jarzab; Halfdan Sorbye; David J Torpy; Vinzenz Stepan; David E Schteingart; Wiebke Arlt; Matthias Kroiss; Sophie Leboulleux; Paola Sperone; Anders Sundin; Ilse Hermsen; Stefanie Hahner; Holger S Willenberg; Antoine Tabarin; Marcus Quinkler; Christelle de la Fouchardière; Martin Schlumberger; Franco Mantero; Dirk Weismann; Felix Beuschlein; Hans Gelderblom; Hanneke Wilmink; Monica Sender; Maureen Edgerly; Werner Kenn; Tito Fojo; Hans-Helge Müller; Britt Skogseid
Journal:  N Engl J Med       Date:  2012-05-02       Impact factor: 91.245

8.  Low-dose monitored mitotane treatment achieves the therapeutic range with manageable side effects in patients with adrenocortical cancer.

Authors:  M Terzolo; A Pia; A Berruti; G Osella; A Alì; V Carbone; E Testa; L Dogliotti; A Angeli
Journal:  J Clin Endocrinol Metab       Date:  2000-06       Impact factor: 5.958

9.  Prognostic role of overt hypercortisolism in completely operated patients with adrenocortical cancer.

Authors:  Alfredo Berruti; Martin Fassnacht; Harm Haak; Tobias Else; Eric Baudin; Paola Sperone; Matthias Kroiss; Thomas Kerkhofs; Andrew R Williams; Arianna Ardito; Sophie Leboulleux; Marco Volante; Timo Deutschbein; Richards Feelders; Cristina Ronchi; Salvatore Grisanti; Hans Gelderblom; Francesco Porpiglia; Mauro Papotti; Gary D Hammer; Bruno Allolio; Massimo Terzolo
Journal:  Eur Urol       Date:  2013-11-14       Impact factor: 20.096

10.  Evolution in functionality of a metastatic pancreatic neuroendocrine tumour (pNET) causing Cushing's syndrome: treatment response with chemotherapy.

Authors:  Surya Panicker Rajeev; Steffan McDougall; Monica Terlizzo; Daniel Palmer; Christina Daousi; Daniel J Cuthbertson
Journal:  BMC Endocr Disord       Date:  2014-08-24       Impact factor: 2.763
View more
  8 in total

Review 1.  Cushing's syndrome: a combined treatment with etomidate and osilodrostat in severe life-threatening hypercortisolemia.

Authors:  Lukasz Dzialach; Joanna Sobolewska; Wioleta Respondek; Agnieszka Wojciechowska-Luzniak; Przemyslaw Witek
Journal:  Hormones (Athens)       Date:  2022-09-21       Impact factor: 3.419

2.  Case Report: Exceptional Response to Second Line Temozolomide Therapy in a Patient With Metastatic Adrenocortical Carcinoma.

Authors:  Deborah Cosentini; Antonella Turla; Ornella Carminati; Salvatore Grisanti; Vittorio Domenico Ferrari; Marta Laganà; Giovanni Rosti; Sandra Sigala; Alfredo Berruti
Journal:  Front Endocrinol (Lausanne)       Date:  2021-04-22       Impact factor: 5.555

Review 3.  Advances in adrenal tumors 2018.

Authors:  J Crona; F Beuschlein; K Pacak; B Skogseid
Journal:  Endocr Relat Cancer       Date:  2018-07       Impact factor: 5.678

4.  CYP11B1 has no role in mitotane action and metabolism in adrenocortical carcinoma cells.

Authors:  Antonina Germano; Laura Saba; Silvia De Francia; Ida Rapa; Paola Perotti; Alfredo Berruti; Marco Volante; Massimo Terzolo
Journal:  PLoS One       Date:  2018-05-07       Impact factor: 3.240

Review 5.  Supportive therapies in patients with advanced adrenocortical carcinoma submitted to standard EDP-M regimen.

Authors:  Antonella Turla; Marta Laganà; Salvatore Grisanti; Andrea Abate; Vittorio Domenico Ferrari; Valentina Cremaschi; Sandra Sigala; Francesca Consoli; Deborah Cosentini; Alfredo Berruti
Journal:  Endocrine       Date:  2022-05-14       Impact factor: 3.925

6.  Metyrapone Versus Osilodrostat in the Short-Term Therapy of Endogenous Cushing's Syndrome: Results From a Single Center Cohort Study.

Authors:  Mario Detomas; Barbara Altieri; Timo Deutschbein; Martin Fassnacht; Ulrich Dischinger
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-13       Impact factor: 6.055

7.  Low-dose etomidate for the management of severe hypercortisolaemia in different clinical scenarios: a case series and review of the literature.

Authors:  Agnieszka Łebek-Szatańska; Karolina M Nowak; Wojciech Zgliczyński; Elżbieta Baum; Agnieszka Żyłka; Lucyna Papierska
Journal:  Ther Adv Endocrinol Metab       Date:  2019-02-08       Impact factor: 3.565

8.  Efficacy of the EDP-M Scheme Plus Adjunctive Surgery in the Management of Patients with Advanced Adrenocortical Carcinoma: The Brescia Experience.

Authors:  Marta Laganà; Salvatore Grisanti; Deborah Cosentini; Vittorio Domenico Ferrari; Barbara Lazzari; Roberta Ambrosini; Chiara Sardini; Alberto Dalla Volta; Carlotta Palumbo; Pietro Luigi Poliani; Massimo Terzolo; Sandra Sigala; Guido Alberto Massimo Tiberio; Alfredo Berruti
Journal:  Cancers (Basel)       Date:  2020-04-10       Impact factor: 6.639
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.